Otenabant
 | |
| Clinical data | |
|---|---|
| ATC code | none |
| Identifiers | |
| |
| CAS Number |
686344-29-6  Y |
| PubChem (CID) | 10052040 |
| ChemSpider |
8227602  N |
| UNII |
J8211Y53EF N |
| KEGG |
D09362 Y |
| ChEMBL |
CHEMBL562668 N |
| Chemical and physical data | |
| Formula | C25H25Cl2N7O |
| Molar mass | 510.4 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| NY (what is this?) (verify) | |
Otenabant (CP-945,598) is a drug which acts as a potent and highly selective CB1 antagonist.[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.[3]
See also
References
- ↑ Kim, M.; et al. (2008), "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist" (PDF), Tetrahedron, 64 (48): 10802–10809, doi:10.1016/j.tet.2008.09.057
- ↑ Woods SC. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction. Journal of the American Academy of Physician Assistants. 2007 Nov;Suppl Endocannabinoid:7-10. PMID 18047036
- ↑ http://www.pfizer.com
| Phytocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Synthetic cannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Allosteric CBR ligands |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Endocannabinoid enhancers (inactivation inhibitors) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anticannabinoids (antagonists/inverse agonists/antibodies) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receptor (ligands) |
| ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transporter (modulators) |
| ||||||||||||||||||
| Enzyme (modulators) |
| ||||||||||||||||||
| Others |
| ||||||||||||||||||
| |||||||||||||||||||
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.